Tuberculosis Clinical Trial
Official title:
Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery
Verified date | December 29, 2017 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study, conducted jointly by researchers at the National Masan TB Hospital, Asan and
Samsung Medical Centers in Seoul, Republic of Korea, and the Yonsei University and the NIH in
the United States, will examine why some patients with tuberculosis (TB) develop disease that
is harder to treat than most cases. TB is an infection of the lung that usually can be
successfully treated with anti-TB drugs. However, some people get a more serious kind of
disease (called multi-drug resistant TB or extensively drug-resistant TB) that is very
difficult to treat and may not be cured by the regular medicines available. This study will
try to find out if some of the common TB drugs are getting to the place where the TB bacteria
are. It will also look at how current anti-TB drugs might be used more effectively and how
better drugs might be developed.
People 20 years of age and older with hard-to-treat TB who have elected to undergo surgical
removal of part of their lung at the National Masan Tuberculosis Hospital, Masan, the Asan
Medical Center, and the Samsung Medical Center, may be eligible for this study.
Participants undergo the following procedures:
- Medical history and physical examination, including sputum sample.
- Blood tests at various times during the study.
- Drug administration. Subjects are given one dose each of five common TB drugs
rifampicin, isoniazid, pyrazinamide, kanamycin and moxifloxacin before they undergo
surgery to remove part of their lung. After surgery, some of the lung tissue and fluid
around the lungs that was removed during surgery will be examined to determine the
regions where the TB bacteria live and analyze the lung tissue itself.
- Dynamic MRI (magnetic resonance imaging) scan. This type of scan uses a magnetic field
and radio waves to produce pictures of the lung. Subjects lie very still on a table
inside the cylindrical scanner with their head on a soft cradle and their hands over
their head. Several images are obtained for less than 5 minutes at a time.
Status | Completed |
Enrollment | 19 |
Est. completion date | December 29, 2017 |
Est. primary completion date | August 26, 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 100 Years |
Eligibility |
- INCLUSION CRITERIA: 1. Males and females age 20 and above 2. Selected for lung resection due to anti-tuberculous treatment failure, multidrug resistant disease, or other reason determined by the treating physician 3. Radiographic evidence of tuberculous disease of the lung(s) 4. If already on an aminoglycoside, ability and willingness to substitute this aminoglycoside with KM for the one study dose 5. Willingness to receive MRI scan and marker and Gadolinium injection 6. Willingness to have samples stored 7. Ability and willingness to give written or oral informed consent EXCLUSION CRITERIA: 1. Subjects less than 20 years of age 2. Women of childbearing potential who are pregnant, breast feeding, or unwilling to avoid pregnancy (i.e., the use of appropriate contraception including oral and subcutaneous implantable hormonal contraceptives, condoms, diaphragm, intrauterine device (IUD), or abstinence from sexual intercourse) [Note: Prospective female participants of childbearing potential must have negative pregnancy test (urine) within 48 hours prior to study entry.] 3. Allergy or hypersensitivity to any of the 5 study drugs, any aminoglycoside, or rifamycin (those allergic to fluoroquinolones will not receive MXF). 4. Those with severe gout 5. Severe claustrophobia or Gadolinium hypersensitivity (tbc) 6. Renal, hepatic, auditory and/or vestibular impairment. 1. Serum creatinine greater than 2.0 mg/dL (renal) 2. Aspartate aminotransferase (AST or SGOT) greater than 100 IU/L (LFTs) 3. Alanine aminotransferase (ALT or SGPT) greater than 100 IU/L (LFTs) 4. Total bilirubin greater than 2.0 mg/dL (LFTs) 7. The use of any of Rifampicin (RIF), Rifapentine or Rifabutin within 30 days prior to the study 8. HIV infection, determined by a positive HIV test performed with the past 6 months 9. The use of any of the following drugs within 30 days prior to study: 1. Systemic cancer chemotherapy 2. Systemic corticosteroids (oral or IV only) with the following exceptions (i.e.the following are NOT exclusion criteria): intranasal, topical, and inhaled corticosteroids, a short course (10 days or less) of corticosteroids for a non-chronic condition completed at least 2 weeks prior to enrollment in this study 3. Systemic IND agents other than Linezolid 4. Antiretroviral medications 5. Growth factors 10. The need for ongoing therapy with warfarin, phenytoin, lithium cholestrymine, levodopa, cimetidine, disulfiram, ergot derivatives, fosphenytoin, carbamazepine, cyclosporine, tacrolimus, sirolimus, amiodarone or Phenobarbital (If a potential subject is on one of these medications but it is being stopped per standard of care, to be eligible for the study the drug must be stopped at least one day prior to receiving study drug. A longer washout period is not necessary.) The only exception to this is amiodarone; because of amiodarone s long half-life and potential for QT prolongation, it should be stopped at least 60 days prior to receiving study drugs. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Pusan National Unversity Hospital (PNUH) | Busan | |
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | National Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) | Asian Medical Center, International Tuberculosis Research Center, Korean Center for Disease Control and Prevention, Novartis Institute for Tropical Medicine |
Korea, Republic of,
Drexler DM, Garrett TJ, Cantone JL, Diters RW, Mitroka JG, Prieto Conaway MC, Adams SP, Yost RA, Sanders M. Utility of imaging mass spectrometry (IMS) by matrix-assisted laser desorption ionization (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):279-88. Epub 2006 Dec 5. — View Citation
Soman A, Honeybourne D, Andrews J, Jevons G, Wise R. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999 Dec;44(6):835-8. — View Citation
Wagner C, Sauermann R, Joukhadar C. Principles of antibiotic penetration into abscess fluid. Pharmacology. 2006;78(1):1-10. Epub 2006 Jul 19. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison between the relative permeability coefficients of RIF and KM in pathologically defined large caseous necrotic nodules. | Dosing given 24 hours- 2 hours before surgery | ||
Secondary | The comparison between the relative permeability coefficients of RIF, KM, INH, PZA and MXF in caseous necrotic nodules versus open cavities | Dosing given 24 hours -2 hours before surgery, then endpoint assessed from time of surgery. | ||
Secondary | The comparison between the absolute permeability coefficients of each of the five drugs in uninvolved lung and in closed necrotic lesions | Dosing given 24 hours -2 hours before surgery, then endpoint assessed from time of surgery. | ||
Secondary | The comparison between the exposure ratio or ratio between the Area Under the Curve (AUC0-24) in lesions (AUClesion), uninvolved lung (AUClung) and plasma (AUCplasma) for RIF and KM in large caseous necrotic nodules | Dosing given 24 hours -2 hours before surgery, then endpoint assessed from time of surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |